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Brain ageing is a complex multifactorial process characterized by gradual and continuous loss of neuronal functions. It is
hypothesized that at the basis of brain ageing as well as age-related diseases, there is an impairment of the antioxidant defense
system leading to an increase of oxidative stress. In this study, two different biological aspects involved in brain ageing and
neurodegeneration have been investigated: oxidative stress and iron accumulation damage. In primary mouse astrocytes, the
stimulation with 50 μM lipoic acid (LA) and 100 nM vitamin D (vitD) was first investigated in a time-course study to determine
the dosages to be used in combination and then in a permeability test using an in vitro blood-brain barrier. In a second set of
experiments, the role of oxidative stress was investigated pretreating astrocytes with 200μM H2O2 for 30min. The ability of
vitD and LA alone and combined together to prevent or repair the damage caused by oxidative stress was investigated after 24 h
of stimulation by the MTT test, mitochondrial membrane potential measurement, and Western blot analysis. To induce
neurodegeneration, cells were pretreated with 300 μM catalytic iron for 6 days and then treated with vitD and LA alone and
combined for additional 6 days to investigate the protection exerted by combination, analyzing viability, ROS production, iron
concentration, and activation of intracellular pathways. In our study, the combination of LA and vitD showed beneficial effects
on viability of astrocytes, since the substances are able to cross the brain barrier. In addition, combined LA and vitD attenuated
the H2O2-induced apoptosis through the mitochondrial-mediated pathway. The combination was also able to counteract the
adverse conditions caused by iron, preventing its accumulation. All these data support the hypothesis of the synergistic and
cooperative activity exerted by LA and vitD in astrocytes indicating a possible new strategy to slow down ageing.
1. Introduction
Ageing is characterized by a progressive loss of physiologi-
cal integrity, leading to impaired function of organs and
systems and increased vulnerability to death. This deterio-
ration is the primary risk factor for major human patholo-
gies including cancer, diabetes, cardiovascular disorders,
and neurodegenerative diseases [1]. Ageing is a multifacto-
rial process, which includes genomic instability, telomere
attrition, epigenetic alterations, loss of protein homeostasis,
deregulated nutrient sensing, mitochondrial dysfunction,
cellular senescence, stem cell exhaustion, and altered inter-
cellular communication [1]. The effect of ageing on the
brain, in particular on molecules, cells, vascularization,
gross morphology, and cognition, is widespread and has
multiple etiologies [2]. It is widely recognized that biologi-
cal ageing is not closely linked to chronological ageing,
and the scientific community is trying to make it possible
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to slow down biological ageing and to reduce the possibility
of suffering from age-related diseases such as the neurode-
generative ones. Cognitive frailty is emerging as one of the
greatest health threats of the twenty-first century. Life expec-
tancy continues to grow, but in the same time, the prevalence
of cognitive decline is increasing [3]. This is becoming a seri-
ous social problem that causes discomfort and increase of
costs for individuals, families, and health systems [4]. Neuro-
degenerative diseases are a heterogeneous group of disorders
characterized by progressive and selective neuronal death
leading to the degeneration of specific brain regions predom-
inantly caused by the natural ageing process [5]. The most
common neurodegenerative diseases are Alzheimer’s disease
(AD) characterized by progressive loss of cognitive functions
[6] and Parkinson’s disease (PD) characterized by motor
symptoms related to dopaminergic neuronal loss in the sub-
stantia nigra [7]. The molecular, cellular, anatomical, and
neurochemical changes in the brain are all associated with
ageing and age-associated diseases [8]. A healthy ageing
brain is characterized by decline in neuronal activity, loss of
synaptic connection and function [9]. In this context, main
important functions are exerted by astrocytes, members of
nonneuronal glial cells, which regulate synaptic formation
and synaptic communication and support neuronal health
and homeostasis [10].
During ageing, both cortical volume and neuronal activ-
ity worsen, and this leads to the atrophy of neuronal den-
drites and to the reduction of the dendritic spine number
[11]. The most important functions of astrocytes include
the recycling of neurotransmitters, support for facilitating
neuronal transmission [12], and the transport of nutrients
such as lipids and sugars to produce energy for neurons
[13]. The functions of astrocytes, so important for the central
nervous system, appear altered in the ageing brain, and this
causes the reduction of neuronal and synaptic functions.
Oxidative stress plays a key role in astrocyte loss; in particu-
lar, it is due to a highly active mitochondria metabolism [14].
The mitochondrial “free radical” theory is one of the
most studied hypotheses to explain the molecular mecha-
nism of ageing; it is based on the endogenous production of
reactive oxygen species (ROS) and their harmful effects on
the mitochondria [15]. Moreover, nitric oxide (NO) when
produced in high concentrations works as a source of toxic
oxidants, called reactive nitrogen species [16]. ROS react with
lipids, proteins, and nucleic acids, causing oxidative damage,
leading to progressive decline of cellular functions [17]. Per-
oxidation of membrane lipids has been hypothesized to be a
major mechanism of ROS attack, resulting in generalized
impairment of the membrane function [18]. On the other
hand, reactive nitrogen species have been involved in diseases
that are related to neurotransmission and cancer where NO is
produced at high concentrations from nonvascular cell
sources. Conversely, NO and drugs that directly or indirectly
increase NO signaling have found clinical applications in
both age-related diseases and in younger individuals [19].
Anyway, the organism possesses defense mechanisms based
on antioxidant actions; a group of enzymatic (e.g., superoxide
dismutase, catalase, and glutathione reductase) or nonenzy-
matic (e.g., glutathione, melatonin, vitamins A, C, and E,
and flavonoids) molecules that plays an important role in
maintaining homeostasis and cell viability [14]. In some
cases, the endogenous antioxidant system is not strong
enough to counteract the oxidative damage caused by ROS
and NO. For this reason, several studies have been conducted
to investigate the effects of antioxidant dietary supplementa-
tion in ageing or neurodegenerative diseases [20, 21]. Indeed,
an increased consumption of specific nutrients such as poly-
phenols, fish and seafood, vitamins, and oligoelements dem-
onstrated protective effects by targeting specific cellular
markers and functions [8].
In scientific literature, a number of clinical data regarding
the effects of supplemental substances (i.e., polyphenols, vita-
mins, oligoelements, and ω-3 polyunsaturated fatty acids) are
available, demonstrating encouraging therapeutic properties
on neurodegenerative processes related to brain ageing [8].
Nutraceutical interventions can slow down physiological
or/and pathological progression due to their antioxidant,
anti-inflammatory, and antiamyloidogenic properties, regu-
lating mitochondrial stress, apoptotic factors, free radical
scavenging system, and neurotrophic factors [8, 22]. Finally,
a mechanism typically present in healthy ageing is the selec-
tive accumulation of iron that occurs in several brain regions
and cell types, with iron mainly bound within ferritin and
neuromelanin [23]. However, the accumulation of iron in
specific brain regions, greater than that reported in healthy
ageing, occurs in many neurodegenerative diseases and is
often associated with oxidative stress and cellular damage
[24]. Whether iron accumulation found in neurodegenera-
tive diseases is a primary event or a secondary effect is
unclear. Ageing is the major risk factor for neurodegenera-
tion. Age-related iron accumulation might be an important
factor that contributes to neurodegenerative processes [24].
In this context, the use of α-lipoic acid (LA) and vitamin
D3, which are well known to exert beneficial effects on the
brain, can be hypothesized. Indeed, both LA and vitamin
D3 are able to cross the blood-brain barrier (BBB) [25, 26],
and several studies have been performed to understand their
functions within the ageing process of the brain [5, 27–29].
Vitamin D or calciferol is a fat-soluble secosteroid syn-
thesized in skin or ingested with food which has only one
active form named vitamin D3 (vitD), cholecalciferol, or
1α,25(OH)2D3 [30]. VitD regulates the expression of numer-
ous target genes through the nuclear vitamin D receptor
(VDR), which controls downstream events including the
protective role against oxidative stress, regulation of autoph-
agic pathways [31], and interplay between apoptosis and sur-
vival pathways [32]. LA (1,2-dithiolane- 3-pentanoic acid) is
a naturally occurring dithiol compound synthesized enzy-
matically in the mitochondrion from octanoic acid. LA’s
antioxidant properties include its ability to directly scavenge
ROS, to regenerate endogenous antioxidants, such as gluta-
thione and vitamins E and C, and to have a metal-chelating
activity [33]. Even on its reduced form, the dihydrolipoic acid
(DHLA) is considered an antioxidant compound [34]. In
addition, brain ageing has been also related to inflammation
[35], induced by ROS that modulates cellular mechanisms
for cell proliferation and survival, death, and immune
responses by inducing the production of proinflammatory
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factors such as cytokines leading to cognitive dysfunctions
and memory loss [36]. Furthermore, excessive secretion of
proinflammatory cytokines has been established to be a cru-
cial promoter of aberrant inflammatory responses in neuro-
degenerative diseases [37]. LA is considered as a potential
anti-inflammatory agent for neurodegenerative conditions
such as Alzheimer’s disease, showing neuroprotective effects
in various neuronal experimental models, and a modulator of
various genes involved in cell survival, inflammation, and
oxidative stress [38]. The aim of this study was to test the effi-
cacy of vitD to prevent the loss of astrocytes during oxidative
stress and iron accumulation. In addition, the ability of LA to
alleviate the effects of oxidative stress, enhance the endoge-
nous antioxidant action, and chelate iron preventing its accu-
mulation in the cells was assessed. Moreover, it was evaluated
whether there is a cooperation between LA and vitD in order
to hypothesize a new human antiageing treatment, such as a
new food supplement called Cebral®.
2. Materials and Methods
2.1. Astrocyte Isolation and Culture. Primary mouse astrocyte
cultures were prepared from both male and female C57BL/6
mouse pups, following a classical technique described else-
where [39] according to the National Guideline for the Use
and Care of Laboratory Animals. Briefly, within 24h of birth,
pups were euthanized, and cortices were dissected, minced,
mechanically digested, and let settle for 30min at room
temperature. Then the cell suspension was centrifuged at
800 rpm for 5min. Pelleted cells were resuspended in Neuro-
nal Basal Medium (Sigma-Aldrich), supplemented with 5%
fetal bovine serum (FBS, Gibco), 1% penicillin/streptomycin
(Sigma-Aldrich), and 2mM L-glutamine (Sigma-Aldrich),
plated in multiwells, and maintained in culture for 6 days
before treatment. Astrocytes should be separated from
microglia and oligodendrocyte precursor cells by shaking,
as reported in literature [40]. For the experiments, 1 × 104
cells on a 96-well plate were plated to study cell viability by
the MTT test, amyloid precursor protein (APP) by the ELISA
test, and ROS production by the colorimetric test; 1 × 104
cells on a black 96-well plate to analyze the oxygen consump-
tion by a fluorescence kit; 1 × 106 on a 6-well plate to deter-
mine the iron concentration by the colorimetric assay;
1 × 106 on a 6-well plate to analyze the intracellular pathways
activated by Western blot analysis; 1 × 106 on a 6-well plate
to analyze p53 activity and ERK/Akt activation; and 4 × 104
on Transwell support to study the permeability, to quantify
vitD and LA. Before stimulations, the cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich) without red phenol and fetal bovine serum (FBS,
Sigma-Aldrich) and supplemented with 1% penicillin/strep-
tomycin (Sigma-Aldrich) and 2mM L-glutamine (Sigma-
Aldrich) in an incubator at 37°C, 5% CO2, and 95% humidity
for 3 h.
2.2. HUVEC Culture. In this study, human umbilical endo-
thelial cells (HUVEC) were also used, in order to obtain a
coculture together with astrocytes as an experimental
in vitro model of BBB. HUVEC were purchased from
ATCC®. Cells were cultured in EGM Media (Lonza) supple-
mented with 10% FBS (Gibco), 1% penicillin/streptomycin
(Sigma-Aldrich), and 2mM glutamine (Sigma-Aldrich) at
37°C in a humidified atmosphere of 95% air, 5% CO2. For
the experiments, 1 × 105 HUVEC cells/cm2 were plated in
the apical compartment of 6.5mm Transwells with a 0.4μm
pore size polyester membrane (Corning Costar, Sigma).
2.3. Experimental Protocol. The cells were used to study two
different biological aspects involved in brain ageing and neu-
rodegeneration: oxidative stress and iron-dependent damage.
In the first set of experiments, the role of vitD and LA under
physiological condition was analyzed. In this step, the dose-
and time-dependent studies (from 15min to 1440min) on
cell viability were performed with LA (from 10μM to
100μM) to determine its optimal concentration, and then
this concentration (50μM) was maintained in all successive
experiments. Then the combination with 50μM LA and
100 nM vitD [41, 42] was investigated in a time-course
study (from 15min to 1440min) and then by the perme-
ability assay to determine each specific concentration
through BBB. In a second set of experiments, the role of
oxidative stress was investigated by pretreatment for
30min with 200μM H2O2 on astrocytes [43]. Particularly,
the ability of vitD and LA alone and combined to prevent
or restore the damage caused by oxidative stress was ana-
lyzed by the MTT test. Moreover, mitochondrial membrane
potential measurement, amyloid precursor protein (APP)
quantification, and Western blot analysis were performed
at 24 h. In a third set of experiments, to induce neurode-
generation, cells were pretreated with catalytic iron (Fe3+)
300μM for 6 days [44] and then treated with vitD and
LA alone and combined for additional 6 days to investi-
gate the protection exerted by the combination, analyzing
viability, ROS production, iron concentration, APP quantifi-
cation, and activated intracellular pathways.
2.4. MTT Test. MTT-based In Vitro Toxicology Assay Kit
(Sigma-Aldrich) was performed on a 96-well plate to deter-
mine cell viability after each stimulation as previously
described [45]. At the end of stimulation, cells were incu-
bated with 1% MTT dye for 2 h at 37°C in an incubator, 5%
CO2, and 95% humidity, and then, the purple formazan crys-
tals were dissolved in equal volume of MTT Solubilization
Solution. Cell viability was determined by measuring the
absorbance at 570nm with correction at 690 nm, through a
spectrometer (VICTOR X4, multilabel plate reader), and cal-
culated by comparing results to the control.
2.5. Blood-Brain Barrier Experimental Model. Astrocytes
were cocultured with HUVEC cells according to methods
reported in literature [46]. In brief, 4 × 104 astrocytes/cm2
were plated on the basolateral side of the flipped 6.5mm
Transwells with a polyester membrane with 0.4μm pore size
(Corning Costar, Sigma-Aldrich) and left to attach for 4 h.
Transwells were then placed into the normal orientation
and the cells left to grow for 48h. After this time, 1 × 105
HUVEC cells/cm2 were plated in the apical compartment.
The inserts were then placed in a 24-well plate. After 7 days
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of culture, the Transwells were treated, and permeability
studies were performed [47]. To understand the ability of
tested substances to cross the blood-brain barrier, the
medium at the bottom side of the Transwells was quantified
over time (from 15min to 1440min) by measuring the vol-
ume and the concentration of vitD and LA.
2.6. Lipoic Acid Determination. The concentration of LA
which crossed to BBB was measured as described in liter-
ature [48]. Briefly, at the end of stimulations, the basolat-
eral volume was analyzed through a spectrometer (VICTOR
X4, multilabel plate reader) at 320nm, and the absor-
bance related to the standard curve was obtained from LA
(200 ng/ml). The results were expressed as means ± SD (%)
of absorption, normalized to the control.
2.7. Vitamin D Quantification. The competitive ELISA assay
kit (FineTest) has been used to detect the metabolically active
form of vitD, such as 25(OH)D3. At the end of each stimula-
tion, 50μl of each sample was collected and immediately
used, following the manufacturer’s instruction. At each sam-
ple, 50μl of biotin-detection and 100μl of SABC working
solution were added and incubated at 37°C for 30min. At
the end, the supernatants were discarded, and then 90μl
TMB substrate plus and 50μl of stop solution were added.
Finally, the 96-well plate was analyzed by a spectrometer at
450nm (VICTOR X4, multilabel plate reader). In addition,
it was necessary to plot a standard curve including the back-
ground (zero well) to perform a quantification.
2.8. ROS Production. The rate of superoxide anion release
was used to examine ROS produced by astrocytes after
stimulations [41]. After treatment, in all samples (treated
or not), 100μl of cytochrome C was added, and in another
sample, 100μl superoxide dismutase was also added for
30min in an incubator (all substances were from Sigma-
Aldrich). The absorbance was measured by a spectrometer
(VICTOR X4, multilabel plate reader), at 550 nm, and O2
was expressed as means ± SD of nanomoles per reduced
cytochrome C per microgram of protein compared to the
control on percentage (%).
2.9. Mitochondrial Membrane Potential. The mitochondrial
membrane potential was analyzed by the Oxygen Consump-
tion/Mito membrane Potential Dual Assay Kit (Cayman
Chemical Company) following manufacturer’s instructions
[49]. The mitochondrial membrane potential was measured
using JC-1 aggregates at an excitation/emission of 560/
590nm and monomers at an excitation/emission of 485/
535nm in a fluorescence spectrometer (VICTOR X4, multi-
label plate reader). The results are expressed as means ± SD
(%) compared to control cells.
2.10. p53 Activity. p53 activity was measured by the specific
ELISA kit (p53 transcription factor assay kit, Cayman Chem-
ical), examining the nuclear extracts obtained at the end of
each stimulation following the manufacturer’s instructions.
The nuclear extraction was obtained by the classical tech-
nique using a complete buffer present in the kit. Briefly, the
cells were lysed with ice-cold 1X Complete Hypotonic Buffer,
supplemented with NP-40, and then centrifuged at 12,000 g
at 4°C for 10min. The pellet was solubilized with ice-cold
Complete Nuclear Extraction Buffer 1x supplemented with
protease and phosphatase inhibitors and then centrifuged at
12,000 g for 15min at 4°C; the supernatant was examined
to analyze the activity of p53 related to the protein quantifi-
cation through the BCA assay (Thermo Fisher).
2.11. Amyloid Precursor Protein (APP) Quantification. Amy-
loid precursor protein (APP) quantification was measured by
the Amyloid Beta A4 protein ELISA kit (Sigma-Aldrich) on
cellular supernatants following the manufacturer’s instruc-
tions. Briefly, at the end of treatments, cellular supernatants
were collected, and each sample was tested with the ELISA
kit. The biotinylated detection antibody specific for the
target protein was added in each well, and the plate was
incubated for 1 hour at room temperature. Then, after
45 minutes of incubation with HRP-conjugated streptavidin,
TMB substrate solution was added for 30 minutes, and sub-
sequently, the reaction was stopped by adding stop solution.
APP concentration was determined by measuring the absor-
bance through a spectrometer (VICTOR X4, multilabel plate
reader) at 450 nm and calculated by comparing results to the
APP standard curve.
2.12. ERK and Akt Activation Assay. ERK/MAPK and PI3K/
Akt activities were measured by the InstantOne™ ELISA
(Thermo Fisher) on cell lysates following the manufacturer’s
instructions [50]. Briefly, cells at the end of treatments were
lysed with 100μl Cell Lysis Buffer Mix, 50μl/well of each
sample was tested in InstantOne ELISA microplate strips,
and at each well, the Antibody Cocktail was added and incu-
bated for 1 h at room temperature on a microplate shaker.
At the end, the Detection Reagent was added to each well,
and after 20min, the reaction was stopped by adding stop
solution to each. The strips were measured by a spectrome-
ter (VICTOR X4, multilabel plate reader) at 450 nm. The
results were expressed as means absorbance (%) compared
to the control.
2.13. Iron Quantification Assay. Iron Assay Kit (Sigma-Al-
drich) which measures ferrous iron (Fe2+), ferric iron
(Fe3+), and total iron (total iron–ferrous iron) in samples
was used on astrocytes following the manufacturer’s instruc-
tions [45]. The absorbance at 593 nm was measured by a
spectrometer (VICTOR X4, multilabel plate reader). Ferric
iron concentrations are equal to the total iron (sample plus
iron reducer)-Fe2+ (sample plus assay buffer). The iron con-
centration was expressed as ng/ml.
2.14. Western Blot. Cells were washed and then lysed in the
ice Complete Tablet buffer (Roche) supplemented with
2mM sodium orthovanadate, 1mM phenylmethanesulfonyl
fluoride (PMSF; Sigma-Aldrich), and 1 : 100 mix Protease
Inhibitor Cocktail (Sigma-Aldrich). From each lysate, 35μg
proteins was resolved into 8% and 15% SDS-PAGE gels,
and polyvinylidene difluoride (PVDF) membranes (GE
Healthcare) were incubated overnight at 4°C with a specific
primary antibody: anti-SOD3 (1 : 250, Santa Cruz), anti-pho-
spho-PKAα/β/γ (Thr198, 1 : 250, Santa Cruz), anti-NOS2
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(1 : 250, Santa Cruz), and anti-cytochrome C (1 : 1000,
Calbiochem). Protein expression was normalized and veri-
fied through β-actin detection (1 : 5000; Sigma-Aldrich) and
expressed as a mean ± SD (% vs. control).
2.15. Statistical Analysis. For each experimental protocol, at
least four independent experiments have been carried out;
the results are expressed as means ± SD of independent
experiments performed on four technical replicates. One-
way ANOVA followed by the Bonferroni post hoc test was
used for statistical analysis, and pairwise differences com-
pared by Mann–Whitney U tests followed by Welch’s test.
p values <0.05 were considered statistically significant.
3. Results
3.1. Cell Viability under Treatments with VitD and LA during
Time. In order to assess the potential effect of vitD and LA
alone and combined on cell viability of astrocytes, the MTT
test was performed both in a dose-response and in a time-
course study. Firstly, the concentration-dependent effect of
LA alone (ranging from 10μM to 100μM) on cell viability
during 24 hours (starting from 15min to 1440min) was
analyzed in order to identify the best concentration to
use. As shown in Figure 1(a), 50μM LA appeared to be the
dose able to induce the greatest effect (p < 0 05) compared
to the control and to other concentrations (10, 25, and
100μM, p < 0 05) during all the time of stimulation, and
the maximum effect of about 66% compared to the control
was observed at 1440min. This concentration of LA was
maintained for all successive experiments. Since the new
hypothesized formulation includes LA and vitD, additional
experiments were carried out to study the combination of
50μM LA and 100nM vitD on cell viability. As reported in
Figure 1(b), vitD increased cell viability of astrocytes in a
time-course manner with a maximum effect, about 22%
(p < 0 05) at 1440min compared to the control. In addition,
the combination of LA and vitD was able to significantly
increase (p < 0 05) cell viability during time compared to
the control (p < 0 05) and to 50μM LA and 100nM vitD
alone starting from 60min of stimulation (p < 0 05). The
combination exerted a greater effect at 1440min compared
to the control (p < 0 05) and to 50μM LA and 100 nM vitD
alone (about 20.5% and 64%, respectively). For this reason,
this time of stimulation was maintained for all successive
experiments. These data support the hypothesis of the syner-
gistic effects exerted by vitD and LA in astrocytes indicating a
possible new strategy to slow down ageing.
3.2. Permeability of VitD and LA through Blood-Brain Barrier
(BBB). A BBB permeability study was performed to better
understand the ability of 100nM vitD and 50μM LA alone
and combined together during time to cross the haematoen-
cephalic barrier. As reported in Figure 2(a), the analysis of
the basolateral volume showed a time-dependent increase
on absorption capacity caused by 100nM vitD and 50μM
LA alone compared to the control (p < 0 05), and the greater
effects were observed at 1440min (about 49.5% and 40.5%,
respectively). The combination of vitD and LA increased
the absorption capacity with respect to the control (p < 0 05)
during time and to their single administration starting from
60min, as previously observed on cell viability (p < 0 05).
These data support a cooperative effect of vitD and LA also
during the permeability assay. The successive quantifications
of vitD and LA were carried out to determine the specific
concentration present in basolateral volume of the BBB
model. In particular, the absorption of vitD and LA during
time was time-dependent, and the combination of vitD and
LA proved to be essential to amplify their ability to cross
the barrier. Indeed, the specific quantifications of vitD
(Figure 2(b)) and LA (Figure 2(c)) showed a greater effect
of the combination compared to the separated administra-
tion (about 26% and 63%, respectively), with a maximum
effect at 1440min (p < 0 05 vs. control). All these findings
support the hypothesis that the combination of LA and vitD
is able to exert beneficial effects directly on viability of astro-
cytes due to their ability to cross the BBB.
3.3. Analysis of Mitochondrial Activity after Treatments with
LA and VitD under Oxidative Condition. Cell viability, ROS
production, and mitochondrial potential were evaluated in
astrocytes, in order to investigate the potential action to pre-
vent cellular ageing under oxidative condition. Exposure to
200μM H2O2 significantly reduced cell viability of about
46% compared to the control; conversely, following post-
treatment with 50μM LA and 100nM vitD alone or com-
bined, the cell viability was significantly increased. The
greatest effect was obtained with the combination of LA
and vitD which reverted the cell loss (Figure 3(a)). Since
the main theory at the basis of brain ageing regards the oxi-
dative condition, additional experiments on ROS production
were performed. 50μM LA, 100nM vitD, and the combina-
tion of both were able to maintain the ROS production under
the physiological level (p > 0 05 vs. control), supporting the
hypothesis of their safety during use (Figure 3(b)). Exposure
of astrocytes to 200μM H2O2 significantly increased the
intracellular ROS production as illustrated in Figure 3(b) of
about 30% compared to the control (p < 0 05); posttreatment
with 50μM LA and 100nM vitD alone significantly reduced
ROS production (about 43% and 57%, respectively, vs. H2O2
alone), and the concomitant administration of LA and vitD
improved the reduction of the ROS level compared to
200μM H2O2, 50μM LA, and 100 nM vitD alone (p < 0 05,
about 78%, 62%, and 50%, respectively). Since the alteration
of the formation of a proton gradient across the inner mito-
chondrial membrane is considered to be one of the key indi-
cators of cellular viability, the mitochondrial potential was
analyzed. Treatments with 50 μM LA, 100 nM vitD, and
with the combination of both induced a significant increase
in red fluorescence, supporting the active role of 50 μM LA,
100 nM vitD, and their combination on mitochondrial activ-
ity (p < 0 05). In addition, the combination of LA and vitD
seems to have a greater effect compared to 50 μM LA and
100 nM vitD alone (about 23% and 60%, respectively).
H2O2-treated cells exhibited changes in the fluorescence sig-
nal which lead to a decreased red fluorescence signal and
increased green fluorescence signal, indicating a significant
dissipation of mitochondrial potential and cell loss compared
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to the control (p < 0 05, Figure 3(c)). Posttreatment with
50 μM LA, 100nM vitD alone, and with the combination
of both significantly reversed dissipation of mitochondrial
potential as shown in Figure 3(c) compared to 200 μM
H2O2 alone (p < 0 05). In particular, the combination of LA
and vitD suppressed the effect of H2O2-induced mitochon-
drial dissipation, shifting the fluorescence signal from green
to red (p < 0 05). These results indicate that the combination
of LA and vitD attenuates the H2O2-induced apoptosis
through the mitochondrial-mediated pathway.
3.4. Study of Intracellular Pathways Activated by LA and VitD
under Oxidative Condition. The dissipation of mitochondrial
potential under oxidative condition is known to initiate a cas-
cade of events leading to the activation of caspases, which in
turn trigger apoptosis. In this context, p53 as a key factor
involved in ageing, oxidative stress, and neurodegeneration
and cytochrome C as a key regulator of both cellular ener-
getic metabolism and apoptosis were investigated in astro-
cytes. Data reported in Figure 4(a) showed a reduction on
p53 activity after the stimulation with 50 μM LA and
100 nM vitD alone and in combination (p < 0 05 vs. control),
supporting previous data about the safety of the combina-
tion. p53 activity significantly increased in H2O2-treated
astrocytes (p < 0 05 vs. control), and the subsequent stimula-
tion with 50 μM LA and 100nM vitD alone significantly
reduced it (p < 0 05). In addition, the combination of LA
and vitD amplified the reduction compared to 200 μM
H2O2 of about 80% and the single administration of about
69% and 60%, respectively (p < 0 05), resulting in survival-
favored conditions. To examine the involvement of the cas-
pase pathways, the expression of cytochrome C was analyzed
under the same conditions. Figures 4(b) and 5 show similar
results for p53 under the stimulation with 50μM LA and
100 nM vitD alone, confirming the previously observed
beneficial effects. The combination of LA and vitD also main-
tained cytochrome C at the basal level, supporting mitochon-
drial integrity. In addition, H2O2-treated cells showed an
increase in the expression of cytochrome C which was
reduced by the following stimulation with both 50μM LA
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Figure 1: Cell viability measured in time-course and dose-response studies in astrocytes. In (a), time-course and dose-response (ranging from
10μM to 100 μM) studies of LA measured in astrocytes are illustrated; in (b), time-course and dose-response studies of 50 μM LA combined
with 100 nM vitD measured in astrocytes are reported. LA= lipoic acid, vitD = vitamin D3, and LA+vitD= combination of lipoic acid and
vitamin D3. Data are expressed as means ± SD (%) of five independent experiments normalized to the control (number 1 in the y axis
corresponds to 100% control values).
6 Oxidative Medicine and Cellular Longevity
and 100nM vitD alone and combined (p < 0 05). In order
to exclude any oxidative damage induced by the stimula-
tions, SOD3 and iNOS expressions were investigated. As
reported in Figures 4(c), 4(d), and 5, the SOD3 and iNOS
expressions significantly increased in the presence of 200
μM H2O2 (p < 0 05 vs. control), supporting the hypothesis
of the involvement of oxidative stress in astrocyte death. In
addition, the poststimulation with 50 μM LA and 100 nM
vitD alone significantly reduced the expression of both
SOD3 and iNOS compared to 200 μM H2O2 alone, and a
greater reduction was obtained by the combined stimulation
with 50 μM LA and 100nM vitD compared to 200 μMH2O2
(p < 0 05), indicating a beneficial effect in counteracting the
ageing process. Since the neuroinflammation is a common
cause of brain ageing, PKA, a key anti-inflammatory marker,
was also investigated under the same conditions (Figures 4(e)
and 5). The expression of PKA observed in astrocytes showed
a significant increase in the presence of both 50 μM LA and
100nM vitD alone (p < 0 05), and their combination ampli-
fied this effect supporting the anti-inflammatory activity of
LA and vitD. In the presence of 200 μM H2O2, a significant
reduction compared to the control was found, and the post-
stimulation with 50 μM LA and 100nM vitD reverted the
mechanism (p < 0 05). The combination of LA and vitD
added after 200 μM H2O2 had a similar effect on PKA
expression to what was observed without H2O2 indicating
the ability of the combination to prevent the induction of
inflammatory cascade under oxidative stress. A natural
consequence of apoptosis is known to be cell loss, and
the β-amyloid analysis demonstrated the alteration in
brain tissue. As reported in Figure 4(f), the stimulation
with 200 μM H2O2 alone caused a significant increase of
the APP level, supporting previous data about cell death.
In addition, the poststimulations with 50 μM LA and
100 nM vitD were able to reduce the damage as shown
by the decrease in the APP level (p < 0 05) compared to
200 μM H2O2 alone. Finally, the greater effect was
observed in the presence of the combined treatment with
LA and vitD, indicating the effectiveness of the combina-
tion during brain damage.
The ERK/MAPK and PI3K-Akt pathways play a crucial
role in the regulation of neuronal and brain survival. 50μM
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LA and 100nM vitD alone confirmed their ability to improve
the viability of cells, activating ERK and Akt mediators, as
reported in Figures 6(a) and 6(b). The combination of LA
with vitD amplified kinase activation compared to the con-
trol and to single administration as well (p < 0 05). Exposure
to 200μMH2O2 significantly reduced ERK and Akt activities
of about 6% and 7%, respectively, compared to the control;
conversely, subsequent posttreatment with 50μM LA and
100nM vitD alone or combined reverted previously observed
effects indicating the activation of survival pathways. In addi-
tion, the combination of LA with vitD showed a greater effect
in PI3/Akt activity compared to ERK/MAPK, supporting the
hypothesis that after the activation of Akt, all neuronal sur-
vival signaling was switched on.
3.5. Evaluation of LA and VitD Activities under Iron
Accumulation. Iron can progressively be accumulated into
the brain during normal ageing; in neurodegenerative disor-
ders, it can be stored in abnormal accumulations. Since LA is
a potent chelator of divalent metal ions and vitD is able to
prevent the damage induced by the accumulation, additional
experiments were performed on astrocytes to verify their
protective ability in the brain. For this reason, cell viability
and ROS production were evaluated in astrocytes after 6 days
of stimulation, as reported in Figures 7(a) and 7(b). Exposure
to 300μM Fe3+ significantly reduced cell viability of about
23% compared to the control (p < 0 05); conversely, follow-
ing posttreatment for additional 6 days with 50μM LA and
100 nM vitD alone, cell viability leads to control values,
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Figure 3: Analysis of cellular viability, ROS production, and mitochondrial activity under oxidative condition. In (a), cell viability, in (b), ROS
production, and in (c), mitochondrial membrane potential measured on astrocytes treated with vitD and LA alone and combined for 24 h
prestimulation with H2O2 are illustrated. The abbreviations are the same as reported in Figure 1. Data are expressed as means ± SD (%) of
five independent experiments normalized to control values (0% line). ∗p < 0 05 vs. control; ∗∗p < 0 05 vs. LA; ϕp < 0 05 vs. vitD; ϕϕp < 0 05
vs. H2O2, bars: p < 0 05 between treatments.
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Figure 4: Kinase activity and densitometric analysis of intracellular pathways involved under oxidative stress. (a) and (f) The measurements
of p53 and APP activities, respectively, measured by the ELISA test. (b–e) Densitometric analysis of cytochrome C, SOD3, iNOS, and p-PKA
expressions obtained by analyzing Western blot on whole astrocyte lysates. The abbreviations are the same as reported in Figure 1. Data are
expressed asmeans ± SD (%) of five independent experiments normalized to control values (0% line) in ELISA experiments and normalized
and verified on β-actin detection in densitometric analysis expressed asmeans ± SD (%). ∗p < 0 05 vs. control; ∗∗p < 0 05 vs. LA; ϕp < 0 05 vs.
vitD; ϕϕp < 0 05 vs. H2O2, bars: p < 0 05 between treatments.
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confirming their ability to chelate iron and repair the damage
(p > 0 05). In addition, the concomitant stimulation with LA
and vitD was able to amplify the beneficial effect exerted by
the single administration (p < 0 05), supporting the idea of
its possible helpful use during brain damage. Additional
experiments on ROS production were performed to investi-
gate the role of oxidation in the presence of iron accumula-
tion. Exposure of astrocytes to 300μM Fe3+ for 6 days
significantly increased the intracellular ROS production, as
illustrated in Figure 7(b) of about 60% compared to the con-
trol (p < 0 05). Moreover, posttreatment for additional 6 days
with 50μM LA and 100 nM vitD alone significantly reduced
ROS production (about 68% and 83%, respectively, vs. Fe3+-
alone), and the concomitant administration of LA and vitD
improved the reduction of the ROS level compared to
300μMFe3+ of about 92%. These findings indicate the ability
of the combination to counteract the oxidative condition
caused by iron accumulation. Since the iron accumulation
is an important cause of brain damage, it is essential to dis-
cover strategies to prevent it; thus, some experiments were
carried out to assess the amount of iron which remains inside
the cells. As reported in Figure 7(c), 300μM Fe3+ increased
the intracellular accumulation after 6 days of stimulation of
about 69% compared to the control (p < 0 05), indicating that
6 days with an excess of iron was a sufficient condition to cre-
ate damage in astrocytes. The poststimulation for additional
6 days with 50μM LA and 100 nM vitD alone significantly
reduced iron accumulation (about 81% and 88%, respec-
tively, vs. Fe3+alone), and the concomitant administration
of LA and vitD improved the prevention of accumulation
compared to 300μM Fe3+ of about 95% and compared to
the single administration (p < 0 05). These findings indicate
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Figure 6: Survival kinase activities measured in astrocytes under oxidative conditions. The quantification of p-ERK (a) and p-Akt (b)
activities measured at 24 h in astrocytes treated with vitD and LA alone and combined under prestimulation with H2O2 is reported. Data
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ϕp < 0 05 vs. vitD; ϕϕp < 0 05 vs. H2O2, bars: p < 0 05 between treatments.
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the ability of the combination to counteract the iron-
dependent damage, preventing its accumulation.
Moreover, to confirm the protection exerted by LA and
vitD, p53 activity was analyzed as well. As shown in
Figure 8(a), 300μM Fe3+ administration for 6 days caused
a significant increase in p53 activity (p < 0 05) compared
to the control, supporting previous observations about the
viability of cells. The poststimulation with 50μM LA and
100nM vitD alone for additional 6 days was able to reduce
the p53 activation (p < 0 05 vs. control) of about 84% and
88%, respectively, compared to 300μM Fe3+. Finally, the
combined effect of LA with vitD for additional 6 days after
300μM Fe3+ was able to amplify the reduction on p53
activity (p < 0 05) compared to 300μM Fe3+ (increased
about 93%) and to the single administration (p < 0 05), sup-
porting the beneficial effects previously observed. The pro-
duction, accumulation, and aggregation of APP during
neurodegeneration are influenced by a number of modula-
tors, and among these is iron, so the level of APP under these
conditions was also detected. As illustrated in Figure 8(b),
exposing astrocytes to 300μM Fe3+ for 6 days significantly
increased the APP level of about 43% compared to the control
(p < 0 05); posttreatment for additional 6 days with 50μMLA
and 100nM vitD significantly reduced the APP level (about
63% and 55%, respectively, vs. 300μM Fe3+ alone), and
the concomitant administration of LA and vitD amplified
the reduction compared to 300μM Fe3+, 50μM LA, and
100 nM vitD alone (p < 0 05, about 82%, 53%, and 61%,
respectively). These findings confirm the importance of the
combination to prevent the iron-dependent damage in the
brain. Cellular oxidative stress and antioxidant enzyme
dysregulation are linked to age-related brain degeneration,
so SOD3 expression was investigated in the same condi-
tions previously reported. The stimulation for 6 days with
300μM Fe3+ caused a significant increase in SOD3 expres-
sion (p < 0 05) compared to the control which was reduced
by the successive stimulation for 6 days more with 50μM
LA or 100nM vitD alone (p < 0 05), indicating a positive
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Figure 7: Cell viability, ROS production, and iron quantification in astrocytes: (a) cell viability, (b) ROS production, and (c) the intracellular
iron quantificationmeasured on astrocytes pretreated with Fe3+ for 6 days and then with vitD and LA alone or combined for additional 6 days.
The abbreviations are the same as reported in Figure 1. Data are expressed asmeans ± SD (%) of five independent experiments normalized to
control values (0% line). ∗p < 0 05 vs. control; ∗∗p < 0 05 vs. LA; ϕp < 0 05 vs. vitD; ϕϕp < 0 05 vs. Fe3+, bars: p < 0 05 between treatments.
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Figure 8: Analysis of the main intracellular pathways analyzed by Western blot and the ELISA kit. In (a), (b), and (d), the measurements of
p53, APP, and ERK/MAPK activities, respectively, are reported by the ELISA test. Data are expressed asmeans ± SD (%) of five independent
experiments normalized to control values (0% line). (c) Densitometric analysis andWestern blot of cytochrome SOD3 expression obtained in
whole astrocyte lysates. Data are expressed asmeans ± SD (%) of five independent experiments normalized and verified on β-actin detection.
The abbreviations are the same as reported in Figure 1. ∗p < 0 05 vs. control; ∗∗p < 0 05 vs. LA; ϕp < 0 05 vs. vitD; ϕϕp < 0 05 vs. Fe3+, bars:
p < 0 05 between treatments.
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effect of 50μM LA and 100nM vitD to maintain a correct
balance of oxidant activity in astrocytes (Figure 8(c)). In
addition, the combined effect of LA with vitD added for
6 days after 300μM Fe3+ was able to significantly reduce
the expression of SOD3 (p < 0 05) compared to both
300μM Fe3+(about 78%) and 50μM LA and 100 nM vitD
alone (about 67% and 40%, respectively). These data allow
to exclude the presence of oxidative damage and inflam-
matory cascade activation in the presence of iron accumu-
lation, supporting the hypothesis that this combination
could be used in human ageing. Finally, the ERK/MAPK
activity was investigated in order to demonstrate that the
combined stimulation with LA and vitD could prevent
iron-dependent cell loss and damage, activating a rescue
mechanism such as the survival pathways. Exposing astro-
cytes to 300μM Fe3+ for 6 days upregulated the ERK/-
MAPK activation as reported in Figure 8(d) (p < 0 05 vs.
control), indicating a negative effect and suggesting that
iron-dependent ROS generation activates this pathway;
poststimulation for additional 6 days with 50μM LA and
100nM vitD alone showed a significant decrease compared
to 300μM Fe3+ (p < 0 05), supporting the beneficial effects
observed previously. In addition, the concomitant adminis-
tration of LA and vitD made the observed attenuation of
overexpression more pronounced compared to 300μM
Fe3+ (p < 0 05), confirming observation of a better survival
of astrocytes after the damage.
4. Discussion
An ageing brain is characterized by a progressive decline
of physiological functions mainly due to the increased
imbalance of the antioxidant defense system along with a
concomitant increase of oxidative stress [14]. Although age-
ing cannot be prevented, many studies seek for strategies to
counteract or slow it down. Indeed, recent studies hypothe-
size the use of antioxidant molecules combined with symp-
tomatic drugs to reduce oxidative stress, thus improving
cognitive functions during ageing and in age-related diseases
[14]. A large body of experimental research indicates that the
brain is highly susceptible to oxidative damage due to high
concentrations of polyunsaturated fatty acids and transition
metals that are involved in the generation of the hydroxyl
radical [51, 52]. In an adult brain, astrocytes are responsible
in maintaining neuronal and synaptic functions [10]. Oxida-
tive stress plays a key role in astrocyte loss, mainly due to the
highly active mitochondria metabolism [14].
According to literature, the brain has a poor catalytic
activity and has low levels of protective antioxidant enzymes;
for this reason, in this work, the efficacy of LA and vitD in
oxidative mechanisms involved in the ageing process was
tested. Indeed, it was demonstrated that the combination of
LA and vitD exerts a synergistic and cooperative effect on
astrocyte activity indicating a possible new strategy to slow
down ageing. The combination of LA and vitD is able to
perform beneficial effects directly on viability of astrocytes,
since these substances are able to cross the blood-brain bar-
rier. Moreover, the combination of LA and vitD increases
the absorption rate of the two substances compared to the
control during time and to their single administration start-
ing from 60min, supporting the cooperative effects of LA
and vitD also during permeability. A recent work by Farr
et al. [29] demonstrated that lipoic acid improves memory
and reverses indices of oxidative stress in old mice but
decreases the lifespan. This feature has not been studied in
this research. This could be a limitation of this research,
which could be addressed in the future. However, vitD, with
its antioxidant action, allows to use lower doses of lipoic acid,
and this could improve the safety of the molecule. Another
limitation of this study could be the use of HUVEC rather
than a brain-derived endothelial cell. However, some studies
indicate that this experimental model can present structural
and functional equivalency with in vivo BBB while still using
HUVEC [53].
Since the main theory at the basis of brain ageing
regards the oxidative stress condition, additional experi-
ments on ROS production were performed. Under oxidative
conditions, treatment with LA and vitD improves the reduc-
tion of the ROS level. The alteration of the formation of a
proton gradient across the inner mitochondrial membrane
is considered to be one of the key indicators of cellular
viability; the combination of LA and vitD suppressed the
effect of H2O2-induced mitochondrial dissipation. Thus, this
study demonstrates that combined LA and vitD can attenu-
ate the H2O2-induced apoptosis through the mitochondrial-
mediated pathways. Furthermore, the specifics to be used
in combination have been determined evaluating the intra-
cellular pathways activated by LA and vitD during oxidative
condition. Our findings suggest that there is a reduction
on p53 activity after the stimulation with LA and vitD that
it is correlated to survival-favored conditions. Moreover,
the involvement of the caspase pathway has been examined
analyzing the expression of cytochrome C. The combination
of LA and vitD is able to reduce cytochrome C expression
during oxidative damage, supporting mitochondrial integ-
rity. Besides, it has been demonstrated that stimulation with
LA and vitD under oxidative condition can reduce cell death
and increase cell survival, by the activation of ERK and Akt
mediators. Even the major pathways (SOD3 and iNOS)
involved in oxidative stress were inhibited by administration
of LA and vitD, indicating better cell survival.
Since neuroinflammation is a common cause of brain
ageing, PKA, a key anti-inflammatory marker, was also inves-
tigated under the same conditions. The cAMP-dependent
PKA signaling is one of the best-characterized signal trans-
duction mechanisms in the central nervous system [54] and
plays a diverse role in neuronal functions, such as regulating
synaptic plasticity, learning, and memory [55]. PKA is a key
phosphorylating enzyme, which triggers a wide variety of
physiological involvement in cell survival, synaptic plastic-
ity, and activation or repression of gene expression [54].
The PKA role in inflammation consists in its involvement
in the cross talk between different signaling mechanisms
such as the inactivation of phospholipase Cβ; the phos-
phorylation of inositol 1,4,5-tris phosphate receptors,
thereby modulating Ca2+ influx; and the phosphorylation
of calcium-calmodulin kinase. In addition, cAMP stimu-
lates mitogen-activated protein kinase activity in cultured
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neurons [54]. In addition, some studies by Salinthone et al.
demonstrated that cAMP/PKA inhibits NF-κB function by
slowing down its translocation into the nucleus and inhibits
NF-κB activity [56].
The expression of PKA observed in astrocytes showed a
significant increase in the presence of LA and vitD, and their
combination amplified this effect, supporting the hypothesis
of an anti-inflammatory activity of combined LA and vitD.
The combination of LA and vitD added after H2O2 had a
similar effect on PKA expression. This finding allows to
exclude the involvement of inflammation cascade during
treatment with LA and vitD combined.
Neuroinflammation and iron accumulation are hall-
marks of a variety of adult neurodegenerative diseases [57],
and particularly, iron is recognized to influence the biochem-
istry of proteins involved in neurodegeneration (for instance,
APP), as well as those playing a crucial role in neuronal
development and efficiency [58]. Moreover, it was demon-
strated that the exposure to Fe3+ significantly reduced cell
viability and increased ROS production and the combination
of LA and vitD can prevent Fe3+-dependent oxidative injury
in astrocytes. It is well known that LA is a potent chelator of
divalent metal ions and vitD is able to prevent the damage
induced by the iron accumulation [41, 59]. However, pro-
cesses involved in age-related and disease-related accumula-
tions of iron and iron-induced inflammation in specific
brain regions and cells are poorly understood. Posttreatment
with LA and vitD was able to restore the damage caused by
iron accumulation. Furthermore, it has been demonstrated
that LA and vitD alone or together were able to prevent intra-
cellular iron accumulation damage by their ability to prevent
iron deposition promoting its elimination (in fact, the treat-
ment was added after 6 days of iron administration). Besides,
even if the presence of iron caused a harmful condition for
the cells, the response to treatment significantly activated
the cellular survival mechanisms (ERK) by switching off apo-
ptosis mechanisms (p53). Indeed, these effects were found to
be mediated by the inhibiting effect of LA on oxidative
(SOD3) and inflammatory (APP) systems.
5. Conclusions
In conclusion, this study demonstrates for the first time
that the combination of LA and vitD is an effective treat-
ment for astrocytes under oxidative stress conditions, indi-
cating the possibility of developing new strategies to treat
brain ageing in all stages. Besides, the combined treatment
with LA and vitD improved the negative effects of preneur-
odegenerative conditions, so there are the preludes to
develop a new formulation to slow down brain ageing
and neurodegenerative diseases, like AD and PD, such as
a new food supplement Cebral®.
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